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ABSTRACT  
N-Methyl-D-aspartate (NMDA) receptors are fundamental for the normal 
function of the central nerve system, and play an important role in memory and 
learning. An overactivation of these receptors will lead to neuronal loss associated with 
major neurological disorders, such as Parkinson’s disease, Alzheimer’s disease, 
schizophrenia, and epilepsy. Herein, twenty two novel enantiopure bicyclic lactams 
were designed, synthesized, and evaluated as NMDA receptor antagonists. Most of the 
new compounds displayed NMDA receptor antagonism and, the most promising 
compound showed IC50 value in the same order of magnitude of memantine, a NMDA 
receptor antagonist used in the clinic for the treatment of Alzheimer’s disease. Further 
biological evaluation indicated that this compound is brain-permeable (determined by 
an in vitro assay) and non-hepatotoxic. All of these results indicate that the (3S,7aS)-7a-
(4-Chlorophenyl)-3-(4-hydroxybenzyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (5b) 
is a potential candidate for the treatment of pathologies associated with the 
overactivation of NMDA receptors. 
 
Keywords: NMDA receptor; Antagonists; Bicyclic lactams; Nitrogen Heterocycles; 
Asymmetric synthesis. 
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Introduction 
N-Methyl-D-aspartate (NMDA) receptors belong to the family of ionotropic 
glutamate receptors (iGluRs) and are localized in the cell membrane of neurons [1]. 
They are typically composed of two GluN1 and two GluN2 subunits, which are further 
subdivided into four types of subunits, labelled as GluN2A-GluN2D. Two GluN3 
subunits (GluN3A and GluN3B) can also be incorporated into the NMDA receptor 
complex [2, 3]. To be activated, NMDA receptors require the binding of the co-agonists 
glycine and glutamate, combined with membrane depolarization, to relieve the blockade 
of Mg2+ and the opening of an ion conductive pore across the membrane bilayer. 
NMDA receptors have a vital role in the normal development of the nerve 
system, being extremely important in sustaining healthy memory, learning, and 
cognition processes [4]. However, the overactivation of these ligand-gated ion channels 
leads to neuronal loss, which is associated with several neurodegenerative disorders, 
including Alzheimer’s and Parkinson’s diseases, and others pathologies, such as stroke, 
schizophrenia, and epilepsy [5]. For this reason, the development of effective NMDA 
receptor antagonists seems to be a promising therapeutic approach to fight these 
diseases where NMDA receptors are overactivated. 
In the last 30 years, several potent NMDA receptor antagonists have been 
developed. Unfortunately, these compounds have presented serious side effects and so it 
has not been possible for these compounds to be used in the clinic [6, 7]. In contrast to 
high-affinity channel blockers, the FDA-approved amantadine and memantine 
(moderate NMDA channel blockers) are well tolerated in the clinic [8, 9].  
The recent elucidation of the NMDA receptor structure [10, 11], together with 
the positive outcomes obtained with memantine in the treatment of Alzheimer’s disease 
[12], has led to a sustained resurgent interest in the development of novel compounds 
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that can suppress NMDA receptors activity during glutamate-induced excitotoxicity 
episodes, while keeping its normal physiological role unharmed. 
 
 
Figure 1. Chemical structure of bicyclic lactams 1a and 2. 
 
In this research area, we have been studying aminoalcohol-derived bicyclic 
lactams as NMDA receptor antagonists. We have previously identified two new 
chemical scaffolds, the (S)-phenylalaninol oxazolopyrrolidone lactam 1a [13] and the 
(R)-tryptophanol-derived oxazolopiperidone lactam 2 [14] (Figure 1), which are around 
1.5-fold more active than amantadine. However, these compounds were still less potent 
than memantine. For these reasons, we decided to synthesize derivatives of 1a with the 
goal of enhancing the NMDA receptor blockade.  
To perform a SAR study, we synthesized and evaluated compounds containing 
different substituents at position C-3, different lactam ring sizes, and different 
substituents at position C-7a (Figure 2).  
 
Figure 2. Synthetic strategy for the optimization of bicyclic lactam 1a. 
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Scheme 1. Synthesis of bicyclic lactams 1a-h, 1a‘-h‘and 5a-b. 
 
Results and Discussion 
Chemistry 
In our previous study, the most active phenylalaninol oxazolopyrrolidone lactam 
detained a phenyl ring at position C-7a of the pyrrolidone [13]. The first derivatizations 
were focused on this phenyl ring, by introducing both electron-withdrawing and 
electron-donating groups. In addition, to validate the importance of having a 
pyrrolidone ring in lactam 1a, we have synthesized derivatives 3 and 3’, possessing a 
piperidone ring instead of pyrrolidone. Moreover, based on the most active compound 
that we obtained from the series of tryptophanol-derived lactams [14], compound 2, we 
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decided to synthesize compounds 4 and 4‘, derived from the (S)-, and (R)-tryptophanol 
amino alcohols, respectively, that contain a phenyl ring at position 8a.  
In order to evaluate the effect on biological activity of introducing a hydroxyl 
group at the aromatic ring (a substituent present at the aromatic ring of the NMDA 
receptor antagonist ifenprodil), we synthesized the equivalent (S)-tyrosinol derivatives 
of the hit compound 1a, and of the most active compound 1c. In particular, two 
oxazolopyrrolidone lactams were synthesized, one with a chlorine atom at para position 
(compound 5b) and the other without any substituent at the phenyl group (compound 
5a). 
To evaluate the importance of the stereochemistry in the biological activity, both 
series of enantiomers were synthesized for most of the compounds, starting from the 
corresponding (S)- or (R)-aminoalcohols. 
The bicyclic lactams 1a-h, 1a’-h’, 3-4, 3’-4’, and 5a-b were easily obtained by 
chiral-induced cyclocondensation reactions between the respective amino alcohol and 
commercially available ketoacids, from moderate to good yields, and excellent 
stereoselectivities (Schemes 1 and 2). 
 
Scheme 2. Synthesis of bicyclic lactams 3-4 and 3’-4’. 
 
Compound 1i (Scheme 3) was synthesized by Suzuki coupling reaction of 
compound 1d with 4-chlorophenylboronic acid. 
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Scheme 3. Synthesis of bicyclic lactam 1i. 
 
Only one diastereoisomer was formed in the cyclocondensation reactions 
(confirmed by 1H-NMR). The absolute configuration of the stereogenic center formed 
during the cyclocondensation reaction was determined using 13C-NMR spectroscopy. In 
particular, the chemical shift of C-7a appears around 101.9-103.2 ppm for compounds 
1a-h and 5a-b, diastereoisomers with 3,7a-(S,S)-relationship. These chemical shift 
values are in accordance with those described in the literature for similar compounds 
[13-16].  
 
Biological activity and SAR study 
To evaluate the potential of the synthesized compounds as NMDA receptor 
antagonists, we measured the ability of compounds in inhibiting the intracellular Ca
2+ 
increase, induced by NMDA, in in vitro cultures of embryonary rat cortical neurons, 
using the Ca
2+
-sensitive, fluorescent dye Fluo-4 (Figure 3 and Table 1). This 
measurement is a reliable protocol to finely monitor intracellular Ca
2+
 oscillations 
induced by an ionotropic stimulus, such as the glutamatergic agonist NMDA, in 
presence or absence of selective NMDA receptors blockers, adaptable for evaluating a 
number of potential blockers in a high throughput screening fashion. 
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Table 1. Effect of bicyclic lactams 1a-h, 1a’-h’, 3, 3‘, 4, 4‘ and 5a-b, at the 
concentration of 100 M, in the NMDA-induced calcium, using in vitro cultures 
of embryonic rat cortical neurons. 
Compound 
NMDA 10 µM 
% Ca
2+
 increase
a
 
Memantine 33 ± 3
***
 
1a 43 ± 4
***
 
1b 46 ± 6
***
 
1c 19 ± 5
***
 
1d 20 ± 4
***
 
1e 42 ± 5
***
 
1f 61 ± 6
***
 
1g 95 ± 4 
1h 55 ± 3
***
 
1i 93 ± 2 
1a’ 54 ± 9
*** 
1b’ 51 ± 5
*** 
1c’ 28 ± 5
***
 
1d’ 22 ± 5
***
 
1e’ 34 ± 5
***
 
1f’ 71 ± 7
***
 
1g’ 95 ± 4 
1h’ 53 ± 5
***
 
3 42 ± 5
***
 
3’ 66 ± 9
***
 
4 35 ± 6
***
 
4’ 34 ± 6
***
 
5a 50 ± 10
***
 
5b 25 ± 13
***
 
a
% Ca
2+
 increase respect to control cells stimulated with NMDA 10 µM in the 
absence of compound. Data are shown as means ± SEM of at least four different 
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cell batches in triplicate. ***p < 0.001, comparing with control in the absence of 
compounds. 
 
 
Figure 3. Effect of bicyclic lactams 1a-h, 1a’-h’, 3, 3‘, 4, 4‘ and 5a-b in the 
NMDA-induced Ca
2+
 increase using in vitro cultures of embryonic rat cortical neurons. 
Data are shown as means ± SEM of at least four different independent experiments in 
triplicate. 
***
p < 0.001, comparing with control in the absence of compounds (white 
bar). 
 
In our first screening, phenylalaninol-derived bicyclic lactams 1a-h and 1a’-h’ 
were evaluated at the concentration of 100 µM. Most compounds significantly 
decreased Ca
2+
 entry. In particular, bicyclic lactams 1c-d, and 1c’-d’ blocked over 70% 
the Ca
2+
 influx, and were more active than memantine (positive control used) and the hit 
compound 1a. In this embryonary cell culture, seeded at a density of 30000 cells per 
well, memantine blocks the Ca
2+
 increase induced by NMDA 10 µM with an IC50 value 
of 47 µM. These results suggest that a halogen atom at para position of the phenyl 
group (chlorine and bromine atoms) has an important role for the activity. Halogens are 
atoms able to fit hydrophobic pockets conveniently, as well as featuring other types of 
interactions, such as the so-called “halogen bond”, as hypothesized in this particular 
situation. The isosteric analogue of 1a, that is the fluorinated 1b, exerts a similar 
blockade to 1a, whilst when we occupy a bulkier space with chlorine or bromine, 
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present in 1c and 1d, the blockade is enhanced. It is important to note that the nature of 
the binding pocket is basically hydrophobic, as methoxy group (-OCH3), present in 1f 
and 1f’, which is thought to be isosteric of the bromine atom, generates a weaker 
blocking effect than its isosteric bromine derivatives or the non-substituted head 
compound 1a. The insertion of a fluorine atom at the meta position (compounds 1h and 
1h’) augmented slightly the blockade effect when compared to the corresponding non-
halogenated counterparts 1f and 1f'. The existence of a hydrophobic binding pocket is 
also confirmed by the fact that derivative 1e’, possessing a methyl group at para 
position, also caused a blocking effect better than compound 1a’. Compounds 1f and 
1f’, with a methoxy group, revealed low impacts over the Ca2+ influx, whilst the 
presence of a methylsulfonyl group (-SO2CH3, compounds 1g and 1g’) led to the 
complete loss of activity.  
As previously observed by us and others, the stereochemistry is an important 
feature for the NMDA receptor antagonist activity [13, 14, 17, 18]. Interestingly, for 
this chemical family, the chlorinated (S)-phenylalaninol derivative 1c revealed to be 
more active than the corresponding (R)-phenylalaninol enantiomer 1c’. However, this 
effect was not so evident for the brominated (S)-phenylalaninol derivative 1d.  
The pyrrolidone ring seems to be important for the blockage of Ca
2+
 entry. In 
fact, compound 3’, containing a piperidone ring, led to higher influx of Ca2+, compared 
with the corresponding pyrrolidone derivative 1a’. However, as the eutomers 3 and 1a 
similarly affected Ca
2+
 influx further studies are needed to better clarify this conclusion. 
Interestingly, the (R)-phenylalaninol derivative 3’ (Figure 3) was much less 
active than the corrresponding (R)-tryptophanol derivative 4’, containing an indole 
moiety instead of a phenyl group in its chemical structure. However, for the (S)- 
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phenylalaninol derivative 3, the replacement of this phenyl group by an indole group 
(i.e. compound 4) did not overly influence the level of activity as NMDA blocker. 
After the first screening, we further synthesized some more derivatives of the 
most promising antagonists, i.e. compounds 1c and 1d. Compound 1i was synthesized 
to evaluate the effect of increasing the distance between the oxazolopyrrolidone 
skeleton moiety and the 4-chlorophenyl substituent on the biological activity study. 
However, this structural modification significantly decreased the blockade of the 
NMDA receptor.  
We have also evaluated the effect of increasing polarity in the structure of 
compound 1c. Starting from (S)-tyrosinol (amino alcohol with a hydroxyl group at the 
para position of the phenyl ring), we obtained two oxazolopirrolidone lactams, one with 
a chlorine atom at the para position (compound 5b) and the other without substituents 
at the phenyl ring (compound 5a) (Scheme 1). The effect of compound 5a in the 
NMDA-induced Ca
2+
 influx increase was not relevant. Very interestingly, the presence 
of a hydroxyl group and the chlorine atom at the oxazolopyrrolidone structure, i.e. 
compound 5b, led to a significant increase of the Ca
2+
 influx. This result further 
confirms that the presence of the hydroxyl group in the phenyl ring is important for the 
interaction with the NMDA receptor, as observed previously for other NMDA receptor 
antagonists described in literature [8, 19]. 
The IC50 values (Table 2) were determined for the most active compounds (1c-d 
and 5b). Compounds 1c and 1d had IC50 values almost in the same order of magnitude 
of memantine (IC50 value of 47 µM) and were 2.3 and 2.5 times more active than the hit 
compound 1a (IC50 value of 91 µM), with IC50 values of 39 and 36 µM, respectively. 
More remarkably, compound 5b presented an IC50 value of 27 µM. These 
improvements are not only of interest because of the augmented blocking effect of the 
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NMDA-induced Ca
2+
 increases, but also these new derivatives can be considered 
longer-lasting potential drugs, as their para positions at phenyl rings are substituted, 
thus avoiding the metabolic actions of CYP enzymes. 
 
 
Table 2. IC50 values (inhibitory concentration able to reduce the NMDA-induced 
Ca
2+
 increase by 50%, calculated by measuring the Ca
2+
 in presence of at least 4 
different concentrations of compound, from 1 to 100 µM) and permeability 
values from the PAMPA-BBB assay Pe (10
-6
 cm s
-1
) of compounds 1c-d and 5b. 
Compound NMDA (10 µM)
a 
PAMPA-BBB assay
b 
 IC50 (µM) Pe (10
-6
 cm s
-1
) CNS Prediction 
1c 39 ± 8 66.2 ± 5.1 cns + 
1d 36 ± 3 14.1 ± 0.7 cns + 
5b 27 ± 1 24.5 ± 1.9 cns + 
1a 91 ± 6 — — 
Memantine 47 ± 3 — — 
a
The values are expressed as means ± SEM of at least four different cell batches 
in triplicate. 
b
Results are the mean ± SD of three independent experiments. 
 
In Vitro Toxicity and Blood–Brain Barrier Permeation Assays 
The brain penetration of the three most promising compounds (compounds 1c, 1d, 
and 5b) was predicted using the in vitro PAMPA-BBB assay described by Di et al. [20], 
and partially modified by Rodríguez-Franco et al. for assaying molecules with limited 
water-solubility [21-23]. The permeability of compounds (Pe) through a lipid extract of 
porcine brain was determined at room temperature by using PBS:ethanol (70:30) as 
solvent and results are gathered in table 2. In the same assay, 10 commercial drugs with 
known CNS penetration were also tested and their values were compared to reported 
values, giving a good linear correlation, Pe (exp.) = 1.30 Pe (bibl.) + 8.61 (R
2
 = 0.87). 
From this equation and following the pattern previously established in the bibliography, 
we could predict compounds as follows: cns + (high BBB permeation) if Pe (10
-6
 cm s
-1
) 
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> 13.8; cns – (low BBB permeation) if Pe (10
-6
 cm s
-1
) < 11.2; and cns +/– (uncertain 
BBB permeation) if Pe (10
-6
 cm s
-1
) is between these values (Table 2). All tested 
compounds showed good CNS-permeability in this in vitro model and thus, it is 
expected they could reach their biological targets in the CNS. 
The in vitro cytotoxicity of compounds 1c, 1d, and 5b was also evaluated (Table 
3) in the human hepatocellular carcinoma HepG2 cell line (an established, well-
characterized toxicological model) [25]. No decrease of cell viability was observed up 
to 100 µM concentration of the three tested compounds, indicating that these 
compounds are non-hepatotoxic for this concentration.  
Table 3. In vitro activity of compounds 1c-d and 5b in HepG2 cell line. 
Compound 25 µM 50 µM 100 µM 
1c 92.1 ± 4.2 92.8 ± 3.1 93.7 ± 3.4 
1d 93.7 ± 1.5 90.2 ± 2.6 93.4 ± 2.7 
5b 96.5 ± 2.2 93.6 ± 3.0 95.5 ± 1.4 
a
The values are expressed as means ± SD for at least 3 independent experiments 
with 3 replicates each. 
 
Conclusions 
A series of enantiopure amino alcohol-derived oxazolopyrrolidones and 
oxazolopiperidones were synthesized and evaluated as NMDA receptor antagonists in 
embryonic rat cortical neurons. Quite remarkably, compounds 1c, 1d, and 5b displayed 
improved activity over the hit compound 1a. The (S)-derivatives were more active than 
the (R)-counterparts as NMDA receptor antagonists. Moreover, halogens at the para 
position of phenyl group in position 7a are preferred to methyl, methoxy, and 
methylsulfonyl groups. The presence of a hydroxyl group (compound 5b) favors the 
activity as antagonist, while the introduction of an aromatic ring between the 
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oxazolopyrrolidone skeleton and the 4-chlorophenyl substituent (compound 1i) results 
in loss of activity.  
In conclusion, several evidences are provided in this work supporting the 
therapeutic potential of bicyclic lactam 5b as NMDA receptor antagonist and its 
potential applicability in the treatment of neurological diseases where NMDA receptors 
are over activated. 
 
Experimental Section 
Chemistry  
General: All reagents and solvents were obtained from commercial suppliers and were 
used without further purification. Triethylamine (NEt3) was dried over KOH under 
nitrogen atmosphere. Melting points were determined using a Kofler camera Bock 
monoscope M. Thin layer chromatography was performed using Merck Silica Gel 60 
F254 plates and visualized by UV light. Merck Silica Gel (200-400 mesh) was used for 
flash column chromatography. 
1
H and 
13
C-NMR spectra were recorded on a Bruker 
Fourier 300. 
1
H and 
13
C NMR chemical shifts are reported in parts per million (ppm, δ) 
referenced to the solvent used. Proton coupling constants (J) are expressed in hertz 
(Hz). Multiplicities are given as: s (singlet), d (doublet), dd (double doublet), t (triplet), 
q (quartet), and m (multiplet). Elemental analyses were performed in a Flash 2000 
CHNS-O ThermoScientific elemental analyzer, at Liquid Chromatography and Mass 
Spectrometry Laboratory, Faculty of Pharmacy of Lisbon University, and are within 
±0.4% of theoretical values. 
 
General Synthetic Procedure for obtaining 1a-h, 1a‘-h‘, 3, 3‘, 4, 4‘, and 5a-b 
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To a solution of the amino alcohol (1.0 equiv.) in toluene was added the 
appropriate keto acid (1.1 equiv). The mixture was heated to reflux for 10-24 h under 
Dean-Stark apparatus. The solvent was removed under reduced pressure and the residue 
obtained was dissolved in ethyl acetate (EtOAc). The organic phase was washed with 
saturated aqueous solutions of NaHCO3 and NaCl, dried with anhydrous Mg2SO4, 
filtered and evaporated. The obtained residue was purified by flash chromatography 
using EtOAc/n-hexane as eluent.  
(3S,7aS)-3-Benzyl-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1a): Following 
the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 0.661 mmol) in 
toluene (5 mL) was added 3-benzoyl propionic acid (0.130 g, 0.734 mmol). Reaction 
time: 16 h. The compound was purified by flash chromatography (EtOAc/n-hexane 1:2) 
to afford the title compound as a pale yellow oil (0.160 g, 82 %); 1H-NMR (300 MHz, 
MeOD) δ 7.53 – 7.46 (m, 2H, ArH), 7.46 – 7.31 (m, 3H, ArH), 7.24 – 7.08 (m, 3H, 
ArH), 7.07 – 7.01 (m, 2H, ArH), 4.41 – 4.27 (m, 1H, H-3), 4.16 (dd, J = 8.7, 7.4 Hz, 1H, 
H-2), 3.57 (dd, J = 8.8, 6.8 Hz, 1H, H-2), 2.93 – 2.76 (m, 1H, CH2), 2.70 (dd, J = 13.7, 
7.1 Hz, 1H, ArCH2), 2.56 – 2.39 (m, 2H, CH2), 2.34 – 2.25 (m, 1H, ArCH2), 2.23 – 2.15 
(m, 1H, CH2), as described in literature [13].  
(3R,7aR)-3-Benzyl-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1a’): 
Following the general procedure, to a solution of (R)-phenylalaninol (0.101 g, 0.667 
mmol) in toluene (5 mL) was added 3-benzoyl propionic acid (0.131 g, 0.734 mmol). 
Reaction time: 24 h. The compound was purified by flash chromatography (EtOAc/n-
hexane 1:2) to afford the title compound as a pale yellow oil (0.157 g, 80 %); 1H-NMR 
spectra was found to be identical to the one obtained for compound 1a [13]. 
(3S,7aS)-3-Benzyl-7a-(4-fluorophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1b): 
Following the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 0.661 
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mmol) in toluene (5 mL) was added 3-(4-fluorobenzoyl) propionic acid (0.143 g, 0.728 
mmol). Reaction time: 23 h. The compound was purified by flash chromatography 
(EtOAc/n-hexane 1:2) to afford the title compound as a yellow oil (0.188 g, 91 %); 
[α]22D = +6.0º (c = 1.1, CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 7.53 – 7.46 (m, 2H, 
ArH), 7.29 – 7.20 (m, 3H, ArH), 7.15 – 7.09 (m, 4H, ArH), 4.45 (dq, J = 9.3, 7.0 Hz, 
1H, H-3), 4.15 (dd, J = 8.8, 7.4 Hz, 1H, H-2), 3.58 (dd, J = 8.8, 7.0 Hz, 1H), 2.95 (dd, J 
= 13.7, 6.2 Hz, 1H), 2.87 – 2.66 (m, 1H), 2.63 – 2.45 (m, 2H), 2.36 – 2.27 (m, 1H), 2.24 
– 2.17 (m, 1H); 13C-NMR (75 MHz, CDCl3) δ 179.98 (C=O), 162.79 (d, J = 246.98 HZ, 
ArCF), 138.60 (ArCq), 137.23 (ArCq), 129.02 (ArCH), 128.67 (ArCH), 127.15 
(ArCH), 127.04 (ArCH), 126.81 (ArCH), 115.87 (ArCH), 115.59 (ArCH), 102.07 (C-
7a), 72.38 (C-2), 56.64 (C-3), 40.05 (ArCH2), 35.21 (CH2), 32.59 (CH2); Anal. Calcd. 
(C19H18FNO2•0.25H2O): C, 72.30%; H, 5.92%; N, 4.44%. Found C, 71.93%; H, 5.84%; 
N, 4.31%. 
(3R,7aR)-3-Benzyl-7a-(4-fluorophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1b’): 
Following the general procedure, to a solution of (R)-phenylalaninol (0.101 g, 0.667 
mmol) in toluene (5 mL) was added 3-(4-fluorobenzoyl) propionic acid (0.144 g, 0.734 
mmol). Reaction time: 22 h. The compound was purified by flash chromatography 
(EtOAc/n-hexane 1:2) to afford the title compound as a yellow oil (0.172 g, 83 %); 
[α]22D = -5.4º (c = 1.1, CH2Cl2); 
1H-NMR spectra was found to be identical to the one 
obtained for compound 1b; Anal. Calcd. (C19H18FNO2•0.2H2O): C, 72.45%; H, 5.90%; 
N, 4.45%. Found C, 72.74%; H, 6.49%; N, 4.94%. 
(3S,7aS)-3-Benzyl-7a-(4-chlorophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)- one (1c): 
Following the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 0.661 
mmol) in toluene (5 mL) was added 3-(4-chlorobenzoyl) propionic acid (0.155 g, 0.728 
mmol). Reaction time: 23 h. The compound was purified by flash chromatography 
 17 
 
(EtOAc/n-hexane 1:2) to give the title compound as a yellow oil in (0.205 g, 95 %); 
[α]22D = +6.0º (c = 1.4, CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 7.37 – 7.29 (m, 4H, 
ArH), 7.19 – 7.08 (m, 3H, ArH), 7.01 – 6.99 (m, 2H, ArH), 4.34 (dq, J = 9.3, 7.0 Hz, 
1H, H-3), 4.05 (dd, J = 8.8, 7.4 Hz, 1H, H-2), 3.47 (dd, J = 8.9, 7.0 Hz, 1H, H-2), 2.84 
(dd, J = 13.7, 6.2 Hz, 1H, ArCH2), 2.78 – 2.65 (m, 1H), 2.53 – 2.35 (m, 2H), 2.26 – 2.18 
(m, 1H), 2.13 – 2.05 (m, 1H); 13C-NMR (75 MHz, CDCl3) δ 179.93 (C=O), 141.39 
(ArCq), 137.16 (ArCq), 134.37 (ArCq), 129.04 (ArCH), 129.00 (ArCH), 128.66 
(ArCH), 126.81 (ArCH), 126.72 (ArCH), 101.96 (C-7a), 72.41 (C-2), 56.66 (C-3), 
40.04 (ArCH2), 35.07 (CH2), 32.54 (CH2); Anal. Calcd. (C19H18ClNO2): C, 69.62%; H, 
5.53%; N, 4.27%. Found C, 69.57%; H, 5.51%; N, 4.44%. 
(3R,7aR)-3-Benzyl-7a-(4-chlorophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(1c’): Following the general procedure, to a solution of (R)-phenylalaninol (0.100 g, 
0.661 mmol) in toluene (5 mL) was added 3-(4-chlorobenzoyl) propionic acid (0.155 g, 
0.728 mmol). Reaction time: 24 h. The compound was purified by flash 
chromatography (EtOAc/n-hexane 1:3) to afford the title compound as a yellow oil 
(0.180 g, 83 %); [α]22D = -5.0º (c = 1.4, CH2Cl2); 
1H-NMR spectra was found to be 
identical to the one obtained for compound 1c; Anal. Calcd. (C19H18ClNO2): C, 69.62%; 
H, 5.53%; N, 4.27%. Found C, 69.72%; H, 5.58%; N, 4.39%.  
(3S,7aS)-3-Benzyl-7a-(4-bromophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1d): 
Following the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 0.661 
mmol) in toluene (5 mL) was added 3-(4-bromobenzoyl) propionic acid (0.187 g, 0.725 
mmol). Reaction time: 25 h. The compound was purified by flash chromatography 
(EtOAc/n-hexane 1:2) to give the title compound as an orange oil (0.246 g, 99.8 %); 
[α]22D = +5.4 º (c = 1.0, CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 7.57 – 7.53 (m, 2H, 
ArH), 7.40 – 7.37 (m, 2H, ArH), 7.28 – 7.19 (m, 3H, ArH), 7.10 – 7.08 (m, 2H, ArH), 
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4.44 (dq, J = 9.3, 7.0 Hz, 1H, H-3), 4.13 – 4.09 (dd, J = 8.2, 7.2 Hz, 1H, H-2), 3.55 (dd, 
J = 8.9, 7.0 Hz, 1H, H-2), 2.92 (dd, J = 13.7, 6.2 Hz, 1H, ArCH2), 2.87 – 2.73 (m, 1H), 
2.62 – 2.43 (m, 2H), 2.32 (dd, J = 13.7, 6.2 Hz, 1H), 2.24 – 2.14 (m, 1H); 13C-NMR (75 
MHz, CDCl3) δ 179.94 (C=O), 141.96 (ArCq), 137.17 (ArCq), 132.02 (ArCH), 129.02 
(ArCH), 128.68 (ArCH), 127.07 (ArCH), 126.83 (ArCH), 122.56 (ArCq), 102.02 (C-
7a), 72.44 (C-2), 56.70 (C-3), 40.06 (ArCH2), 35.06 (CH2), 32.55 (CH2); Anal. Calcd. 
(C19H18BrNO2•0.4H2O): C, 60.13%; H, 5.00%; N, 3.69%. Found C, 60.01%; H, 4.90%; 
N, 4.00%  
(3R,7aR)-3-Benzyl-7a-(4-bromophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(1d’): Following the general procedure, to a solution of (R)-phenylalaninol (0.101 g, 
0.669 mmol) in toluene (5 mL) was added 3-(4-bromobenzoyl) propionic acid (0.189 g, 
0.736 mmol). Reaction time: 26 h. The compound was purified by flash 
chromatography (EtOAc/n-hexane 1:3) to afford the title compound as a yellow oil 
(0.189 g, 75.2 %); [α]22D = -4.7º (c = 1.1, CH2Cl2); 
1H-NMR spectra was found to be 
identical to the one obtained for compound 1d; Anal. Calcd. (C19H18BrNO2): C, 
61.30%; H, 4.87%; N, 3.76%. Found C, 61.19%; H, 4.94%; N, 3.71%. 
(3S,7aS)-3-Benzyl-7a-(p-tolyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1e): 
Following the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 0.661 
mmol) in toluene (5 mL) was added 3-(4-methylbenzoyl) propionic acid (0.140 g, 0.728 
mmol). Reaction time: 25 h. The compound was purified by flash chromatography 
(EtOAc/n-hexane 1:2) to give the title compound as an yellow oil (0.189 g, 93.2 %); 
[α]22D = +1.4 º (c = 1.5, CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 7.40 – 7.38 (m, 2H, 
ArH), 7.27 – 7.18 (m, 5H, ArH), 7.11 – 7.08 (m, 2H, ArH), 4.41 (dq, J = 9.3, 7.0 Hz, 
1H, H-3), 4.12 – 4.07 (dd, J = 8.8, 7.0 Hz, 1H, H-2), 3.58 (dd, J = 8.8, 7.0 Hz, 1H, H-2), 
2.96 (dd, J = 13.7, 6.2 Hz, 1H, ArCH2), 2.88 – 2.75 (m, 1H), 2.60 – 2.43 (m, 2H), 2.40 
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(s, 3H, CH3), 2.35 – 2.17 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ 179.98 (C=O), 139.73 
(ArCq), 138.20 (ArCq), 137.50 (ArCq), 129.49 (ArCH), 129.06 (ArCH), 128.62 
(ArCH), 126.71 (ArCH), 125.17 (ArCH), 102.44 (C-7a), 72.39 (C-2), 56.59 (C-3), 
40.07 (ArCH2), 35.32 (CH2), 32.74 (CH2); Anal. Calcd. (C20H21NO2•0.15H2O): C, 
77.52%; H, 6.94%; N, 4.52%. Found C, 77.35%; H, 6.95%; N, 4.44%.  
(3R,7aR)-3-Benzyl-7a-(p-tolyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1e’): 
Following the general procedure, to a solution of (R)-phenylalaninol (0.100 g, 0.661 
mmol) in toluene (5 mL) was added 3-(4-methylbenzoyl) propionic acid (0.140 g, 0.728 
mmol). Reaction time: 26 h. The compound was purified by flash chromatography 
(EtOAc/n-hexane 1:2) to give the title compound as a yellow oil (0.152 g, 75 %); [α]22D 
= -3.2 º (c = 1.4, CH2Cl2); 
1H-NMR spectra was found to be identical to the one 
obtained for compound 1e. Anal. Calcd. (C20H21NO2): C, 78.15%; H, 6.89%; N, 4.56%. 
Found C, 78.10%; H, 7.13%; N, 4.76%.  
(3S,7aS)-3-Benzyl-7a-(4-methoxyphenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(1f): Following the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 
0.661 mmol) in toluene (5 mL) was added 3-(4-methoxylbenzoyl) propionic acid (0.153 
g, 0.735 mmol). Reaction time: 23 h. The compound was purified by flash 
chromatography (EtOAc/n-hexane 1:2) to give the title compound as an yellow oil 
(0.171 g, 80 %); [α]22D = +1.6 º (c = 0.5, CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 7.43 – 
7.40 (m, 2H, ArH), 7.27 – 7.18 (m, 3H, ArH), 7.11 – 7.08 (m, 2H, ArH), 6.96 – 6.93 (m, 
2H, ArH), 4.41 (dq, J = 9.3, 7.0 Hz, 1H, H-3), 4.12 (dd, J = 8.8, 7.0 Hz, 1H, H-2), 3.85 
(s, 3H, OCH3), 3.58 (dd, J = 8.8, 7.0 Hz, 1H, H-2), 2.96 (dd, J = 13.7, 6.2 Hz, 1H, 
ArCH2), 2.88 – 2.74 (m, 1H), 2.60 – 2.43 (m, 2H), 2.36 – 2.16 (m, 2H); 
13C-NMR (75 
MHz, CDCl3) δ 179.99 (C=O), 159.67 (ArCq), 137.45 (ArCq), 134.72 (ArCq), 129.04 
(ArCH), 128.61 (ArCH), 126.70 (ArCH), 126.52 (ArCH), 114.07 (ArCH), 102.32 (C-
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7a), 72.34 (C-2), 56.56 (C-3), 55.46 (OCH3), 40.06 (ArCH2), 35.31 (CH2), 32.70 (CH2); 
Anal. Calcld. (C20H21NO3•0.15H2O): C, 73.66%; H, 6.60%; N, 4.30%. Found C, 
73.32%; H, 6.63%; N, 4.32%.  
(3R,7aR)-3-Benzyl-7a-(4-methoxyphenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(1f’): Following the general procedure, to a solution of (R)-phenylalaninol (0.102 g, 
0.675 mmol) in toluene (5 mL) was added 3-(4-methoxybenzoyl) propionic acid (0.153 
g, 0.735 mmol). Reaction time: 22 h. The compound was purified by flash 
chromatography (EtOAc/n-hexane 1:2) to give the title compound as a yellow oil (0.160 
g, 73 %); [α]22D = -2.4 º (c = 0. 6, CH2Cl2); 
1H-NMR spectra was found to be identical 
to the one obtained for compound 1f; Anal. Calcd. (C20H21NO3): C, 74.28%; H, 6.55%; 
N, 4.33%. Found C, 73.97%; H, 6.57%; N, 4.33%. 
(3S,7aS)-3-Benzyl-7a-(4-(methylsulfonyl)phenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-
one (1g): Following the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 
0.661 mmol) in toluene (5 mL) was added 3-(4-methylsulfonylbenzoyl) propionic acid 
(0.186 g, 0.727 mmol). Reaction time: 22 h. The compound was purified by flash 
chromatography (EtOAc/n-hexane 3:1) and recrystallized from EtOAc/n-hexane to give 
the title compound as a white crystalline solid (0.216 g, 88 %); [α]22D = +10.5º (c = 1.0 
CH2Cl2); mp: 159-161 °C; 
1H-NMR (300 MHz, CDCl3) δ 7.95 – 7.91 (m, 2H, ArH), 
7.67 – 7.62 (m, 2H, ArH), 7.20 – 7.12 (m, 3H, ArH), 7.02 – 6.99 (m, 2H, ArH), 4.40 
(dq, J = 9.1, 6.9 Hz, 1H, H-3), 4.11 (dd, J = 8.9, 7.3 Hz, 1H, H-2), 3.49 (dd, J = 8.9, 7.0 
Hz, 1H, H-2), 3.05 (s, 3H, SO2CH3), 2.83 (dd, J = 13.7, 6.3 Hz, 1H, ArCH2), 2.77-2.68 
(m, 1H), 2.58 – 2.41 (m, 2H), 2.25 (dd, J = 13.9, 8.8 Hz, 1H), 2.17 – 2.07 (m, 1H); 13C-
NMR (75 MHz, MeOD) δ 182.22 (C=O), 150.16 (ArCq), 142.11 (ArCq), 138.49 
(ArCq), 130.08 (ArCH), 129.53 (ArCH), 129.06 (ArCH), 127.69 (ArCH), 127.47 
(ArCH), 103.23 (C-7a), 73.45 (C-2), 58.22 (C-3), 44.29 (SO2CH3), 40.56 (ArCH2), 
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36.00 (CH2), 33.21 (CH2); Anal. Calcd. (C20H21NO4S•0.05H2O): C, 64.51%; H, 5.72%; 
N, 3.76%. Found C, 64.24%; H, 5.62%; N, 3.89%.  
(3R,7aR)-3-Benzyl-7a-(4-(methylsulfonyl)phenyl)tetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (1g’): Following the general procedure, to a solution of (R)-phenylalaninol 
(0.101 g, 0.665 mmol) in toluene (5 mL) was added 3-(4-methylsulfonylbenzoyl) 
propionic acid (0.188 g, 0.732 mmol). Reaction time: 24 h. The compound was purified 
by flash chromatography (EtOAc/n-hexane 2:1) and recrystallized from EtOAc/n-
hexane to give white crystalline solid (0.171 g, 69 %); [α]22D = -13.6º (c = 1.0 CH2Cl2); 
mp: 160-161 °C; 1H-NMR spectra was found to be identical to the one obtained for 
compound 1g. Anal. Calcd. (C20H21NO4S): C, 64.67%; H, 5.70%; N, 3.77%. Found C, 
65.01%; H, 5.81%; N, 3.80%.  
(3S,7aS)-3-Benzyl-7a-(3-fluoro-4-methoxyphenyl)tetrahydropyrrolo[2,1-b]oxazol- 
5(6H)-one (1h): Following the general procedure, to a solution of (S)-phenylalaninol 
(0.100 g, 0.661 mmol) in toluene (5 mL) was added 3-(3-fluoro-4-methoxybenzoyl) 
propionic acid (0.165 g, 0.727 mmol). Reaction time: 20 h. The compound was purified 
by flash chromatography (EtOAc/n-hexane 1:2) to give the title compound as a yellow 
oil (0.198 g, 88 %); [α]22D = +5.1 º (c = 1.3, CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 
7.25 – 7.17 (m, 4H, ArH), 7.16 – 7.10 (m, 2H, ArH), 7.08 – 7.05 (m, 2H, ArH), 4.33 
(dq, J = 9.3, 7.1 Hz, 1H, H-3), 4.19 – 4.13 (m, 1H, H-2), 3.88 (s, 3H, OCH3), 3.61-3.55 
(m, 1H, H-2), 2.90-2.78 (m, 2H, ArCH2), 2.52 – 2.32 (m, 3H), 2.23 – 2.13 (m, 1H); 
13C-
NMR (75 MHz, CDCl3) δ 179.88 (C=O), 152.48 (d, J = 238.5 Hz, ArCF), 147.64 (d, J = 
10.7 Hz, ArCOMe), 137.21 (ArCq), 135.79 (d, J = 5.25 Hz, ArCq), 128.99 (ArCH), 
128.61 (ArCH), 126.75 (ArCH), 120.96 (d, J = 3.75 Hz, ArCH), 113.42 (d, J = 4.5 Hz, 
ArCH), 113.36 (ArCH), 113.19 (ArCH), 101.74 (C-7a), 72.39 (C-2), 56.62 (OCH3), 
56.40 (C-3), 40.03 (ArCH2), 35.09 (CH2), 32.53 (CH2); Anal. Calcd. 
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(C20H20FNO3•0.3H2O): C, 69.26%; H, 6.00%; N, 4.04%. Found C, 69.04%; H, 5.77%; 
N, 4.21%.  
((3R,7aR)-3-Benzyl-7a-(3-fluoro-4-methoxyphenyl)tetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (1h’): Following the general procedure, to a solution of (R)-phenylalaninol 
(0.100 g, 0.661 mmol) in toluene (5 mL) was added 3-(3-fluoro-4-methoxybenzoyl) 
propionic acid (0.165 g, 0.727 mmol). Reaction time: 24 h. The compound was purified 
by flash chromatography (EtOAc/n-hexane 2:3) to give the title compound as a yellow 
oil (0.184 g, 82 %); [α]22D = -4.2 º (c = 1.3, CH2Cl2); 
1H-NMR spectra was found to be 
identical to the one obtained for compound 1h. Anal. Calcd. (C20H20FNO3): C, 70.37%; 
H, 5.91%; N, 4.10%. Found C, 70.14%; H, 6.44%; N, 4.22%. 
(3S,8aS)-3-Benzyl-8a-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one (3): Following 
the general procedure, to a solution of (S)-phenylalaninol (0.100 g, 0.661 mmol) in 
toluene (5 mL) was added 4-benzoylbutyric acid (0.140 g, 0.728 mmol). Reaction time: 
23 h. The compound was purified by flash chromatography (EtOAc/n-hexane 1:2) and 
recrystallized from EtOAc/n-hexane to give white crystalline solid (0.176 g, 87 %); 
[α]22D = -5.2º (c = 1.2 CH2Cl2); mp: 138-140 °C; 
1H-NMR (300 MHz, CDCl3) δ 7.25 – 
7.19 (m, 5H, ArH), 7.05 – 6.95 (m, 3H, ArH), 6.88 – 6.85 (m, 2H, ArH), 4.34 – 4.23 (m, 
1H, H-3), 3.70 (dd, J = 9.0, 7.7 Hz, 1H, H-2), 3.38 (dd, J = 12.9, 3.6 Hz, 1H, H-2), 3.11 
(t, J = 8.9 Hz, 1H), 2.44 (dd, J = 18.6, 6.9 Hz, 1H, ArCH2), 2.24 (ddd, J = 18.7, 11.1, 7.7 
Hz, 1H), 2.03 – 1.95 (m, 1H), 1.74 – 1.64 (m, 1H), 1.58 – 1.50 (m, 2H), 1.47 – 1.23 (m, 
1H); 13C-NMR (75 MHz, CDCl3) δ 170.19 (C=O), 141.77 (ArCq), 137.86 (ArCq), 
128.97 (ArCH), 128.63 (ArCH), 128.43 (ArCH), 126.74 (ArCH), 126.64 (ArCH), 96.47 
(C-8a), 68.63 (C-2), 57.60 (C-3), 39.20 (ArCH2), 36.49 (CH2), 31.06 (CH2), 15.91 
(CH2); Anal. Calcd. (C20H21NO2): C, 78.15%; H, 6.89%; N, 4.56%. Found C, 77.81%; 
H, 6.97%; N, 4.53%. 
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(3R,8aR)-3-Benzyl-8a-phenyltetrahydro-2H-oxazolo[3,2-a]pyridin-5(3H)-one (3’): 
Following the general procedure, to a solution of (R)-phenylalaninol (0.100 g, 0.661 
mmol) in toluene (5 mL) was added 4-benzoylbutyric acid (0.140 g, 0.728 mmol). 
Reaction time: 23 h. The compound was purified by flash chromatography (EtOAc/n-
hexane 2:3) and recrystallized from EtOAc/n-hexane to give white crystalline solid 
(0.176 g, 86 %); [α]22D = +7.1 º (c = 1.2, CH2Cl2); mp: 139-141 °C; 
1H-NMR spectra 
was found to be identical to the one obtained for compound 3. Anal. Calcld. 
(C20H21NO2): C, 78.15%; H, 6.89%; N, 4.56%. Found C, 78.53%; H,6.90 %; N, 4.66%.  
(3S,8aS)-3-((1H-Indol-3-yl)methyl)-8a-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-
one (4): Following the general procedure, to a solution of (S)-tryptophanol (0.100 g, 
0.53 mmol) in toluene (5 mL) was added 4-benzoylbutyric acid (0.113 g, 0.59 mmol). 
Reaction time: 21 h. The compound was purified by flash chromatography (EtOAc/n-
hexane 1:1) and recrystallized from EtOAc/n-hexane to give white crystalline solid 
(0.132 g, 72 %); [α]22D = -29.2 º (c =1.0, CH2Cl2); mp: 165-167 ºC; 
1H NMR (300 MHz, 
CDCl3) δ 7.95 (s, 1H, NH), 7.65 (d, J = 7.9 Hz, 1H, ArH), 7.52 – 7.37 (m, 5H, ArH), 
7.34 – 7.22 (m, 1H, ArH), 7.22 – 7.04 (m, 4H, ArH), 6.83 (d, J = 2.1 Hz, 1H, ArH), 4.74 
– 4.59 (m, 1H, H-3), 3.94 (dd, J = 9.0, 7.7 Hz, 1H, H-2), 3.68 (ddd, J = 13.7, 3.5, 1.0 
Hz, 1H), 3.35 (t, J = 8.7 Hz, 1H), 2.69 (dd, J = 18.7, 7.1 Hz, 1H, ArCH2), 2.56 – 2.38 
(m, 2H), 2.22 (dt, J = 12.5, 3.0 Hz, 1H), 1.92 (ddd, J = 14.1, 12.6, 3.6 Hz, 1H), 1.77 
(dddd, J = 9.8, 7.6, 3.7, 2.2 Hz, 1H), 1.66 – 1.45 (m, 1H); 13C NMR (75 MHz, MeOD) δ 
172.59 (C=O), 142.94 (ArCq), 138.06 (ArCq), 129.67 (ArCq), 129.42 (ArCH), 128.57 
(ArCH), 127.84 (ArCH), 123.34 (ArCH), 122.46 (ArCH), 119.69 (ArCH), 119.47 
(ArCH), 112.22 (ArCH), 111.61 (ArCq), 97.71 (C-9b), 69.97 (C-2), 58.04 (C-3), 37.33 
(ArCH2), 31.58 (CH2), 29.72 (CH2), 16.65 (CH2); Anal. Calcd. (C22H22N2O2): C, 
76.28%; H, 6.40%; N, 8.09%. Found C, 76.05%; H, 6.55%; N, 8.23%. 
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(3R,8aR)-3-((1H-Indol-3-yl)methyl)-8a-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-
one (4’): Following the general procedure, to a solution of (R)-tryptophanol (0.100 g, 
0.53 mmol) in toluene (5 mL) was added 4-benzoylbutyric acid (0.113 g, 0.59 mmol). 
Reaction time: 21 h. The compound was purified by flash chromatography (EtOAc/n-
hexane 1:1) and recrystallized from EtOAc/n-hexane to give white crystalline solid 
(0.136g, 74.5%); [α]22D = +32.3 º (c = 1.0, CH2Cl2); mp: 166-168 ºC; 
1H-NMR spectra 
was found to be identical to the one obtained for compound 4.  Anal. Calcd. 
(C22H22N2O2): C, 76.28%; H, 6.40%; N, 8.09%. Found C, 76.24%; H, 6.17%; N, 8.24%. 
(3S,7aS)-3-(4-Hydroxybenzyl)-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(5a): Following the general procedure, to a solution of (S)-tyrosinol hydrochloride 
(0.061 g, 0.299 mmol) in toluene (3 mL) was added anhydrous triethylamine (45.9 µL, 
0.329 mmol). At 60 ºC was added 3-benzoylpropionic acid (0.064 g, 0.359 mmol). 
Reaction time: 24 h. The compound was purified by flash chromatography (EtOAc/n-
hexane 1:2) to afford the title compound as a white powder (0.018 g, 19.4 %); mp: 163-
164 ºC; 1H-NMR (300 MHz, CDCl3) δ 7.53 – 7.49 (m, 2H, ArH), 7.47 – 7.36 (m, 3H, 
ArH), 6.99 – 6.95 (m, 2H, ArH), 6.76 – 6.71 (m, 2H, ArH), 5.63 (s, 1H, ArOH), 4.41 
(dq, J = 9.3, 7.0 Hz, 1H, H-3), 4.18 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.59 (dd, J = 8.7, 6.8 
Hz, 1H, H-2), 2.92 – 2.74 (m, 2H), 2.64 – 2.46 (m, 2H), 2.32 – 2.20 (m, 2H); 13C-NMR 
(75 MHz, CDCl3) δ 180.51 (C=O), 155.15 (ArCq), 142.44 (ArCq), 130.10 (ArCH), 
128.96 (ArCq), 128.85 (ArCH), 128.50 (ArCH), 125.14 (ArCH), 115.54 (ArC), 102.53 
(C-7a), 72.52 (C-2), 56.82 (C-3), 39.09 (ArCH2), 35.18 (CH2), 32.78 (CH2); Anal. 
Calcd. (C19H19NO3): C, 73.77%; H, 6.19%; N, 4.53%. Found C, 73.88%; H, 6.57%; N, 
4.68%. 
(3S,7aS)-7a-(4-Chlorophenyl)-3-(4-hydroxybenzyl)tetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (5b): Following the general procedure, to a solution of (S)-tyrosinol 
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hydrochloride (0.032 g, 0.156 mmol) in toluene (2 mL) was added anhydrous TEA 
(24.0 µL, 0.172 mmol). At 60 ºC was added 3-(4-chlorobenzoyl) propionic acid (0.040 
g, 0.187 mmol). Reaction time: 24 h. The compound was purified by flash 
chromatography (EtOAc/n-hexane 1:2) to afford the title compound as a white powder 
(0.016 g, 29.1 %); mp: 186-187 ºC; 1H-NMR (300 MHz, CDCl3) δ 7.45 – 7.35 (m, 4H, 
ArH), 6.98 – 6.93 (m, 2H, ArH), 6.74 – 6.70 (m, 2H, ArH), 5.31 (s, OH), 4.44 – 4.34 
(m, 1H, H-3), 4.15 (dd, J = 8.6, 7.6 Hz, 1H, H-2), 3.55 (dd, J = 8.7, 6.9 Hz, 1H, H-2), 
2.88 – 2.74 (m, 2H), 2.62 – 2.43 (m, 2H), 2.30 – 2.14 (m, 2H); 13C-NMR (75 MHz, 
CDCl3) δ 180.42 (C=O), 155.05 (ArCq), 141.19 (ArCq), 134.45 (ArCq), 130.10 
(ArCH), 129.07 (ArCH), 128.80 (ArCq), 126.80 (ArCH), 115.58 (ArCH), 102.06 (C-
7a), 72.45 (C-2), 56.90 (C-3), 39.11 (ArCH2), 35.18 (CH2), 32.64 (CH2); Anal. Calcd. 
(C19H18ClNO3): C, 66.38%; H, 5.28%; N, 4.07%. Found C, 66.19%; H, 5.22%; N, 
3.94%. 
 
Synthetic Procedure for obtaining (3S,7aS)-3-benzyl-7a-(4'-chloro-[1,1'-biphenyl]-4-
yl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (1i) 
To a solution of bicyclic lactam 1d (0.051 g, 0.137 mmol, 1 equiv.) in dioxane (1.6 mL) 
was added Pd(PPh3)2Cl2 (5 mg, 16.3 µmol, 0.1 equiv.), Na2CO3 1 M (420 µL) and 4-
chlorophenylboronic acid (0.027 g, 0.173 mmol, 1.2 equiv.). The resulting mixture was 
degassed and stirred at 100 ºC during 4 h under N2 atmosphere. After cooling to room 
temperature, the reaction mixture was diluted with CH2Cl2, filtered under celite and 
concentrated under pressure to give the crude product. The crude was absorbed on silica 
and purified by flash chromatography (EtOAc/n-hexane 2:3) to afford the title 
compound as a colorless oil (0.045 g, 82.0 %); 1H-NMR (300 MHz, CDCl3) δ 7.47 – 
7.39 (m, 6H, ArH), 7.29 – 7.26 (m, 2H, ArH), 7.12 – 7.01 (m, 3H, ArH), 6.96 – 6.94 (m, 
 26 
 
2H, ArH), 4.30 (dq, J = 9.0, 7.0 Hz, 1H, H-3), 4.01 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.46 
(dd, J = 8.8, 7.1 Hz, 1H, H-2), 2.82 (dd, J = 13.7, 6.2 Hz, 1H, ArCH2), 2.75 – 2.62 (m, 
1H), 2.48 – 2.32 (m, 2H), 2.24– 2.05 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 179.95 
(C=O), 142.08 (ArCq), 140.06 (ArCq), 138.96 (ArCq), 137.3q (ArCq), 133.81 (ArCq), 
129.14 (ArCH), 129.02 (ArCH), 128.62 (ArCH), 128.45 (ArCH), 127.36 (ArCH), 
126.75 (ArCH), 125.81 (ArCH), 102.25 (C-7a), 72.45 (C-2), 56.65 (C-3), 40.05 
(ArCH2), 35.21 (CH2), 32.62 (CH2); Anal. Calcd. (C25H22ClNO2): C, 74.34%; H, 
5.49%; N, 3.47%. Found C, 74.66%; H, 5.58%; N, 3.47%.  
 
Biology  
NMDA receptor antagonist activity: Pregnant rats (18 days) were sacrificed by 
decapitation under a procedure that follows the European Union Council Directive 
issued for these purposes, and approved by the Ethics Committee of the School of 
Medicine, University Autonoma of Madrid, Spain. Efforts to reduce the number of 
animals and their suffering were made. Embryos were immediately extracted from the 
womb by caesarean section and their brains were carefully dissected out. Meninges 
were removed, and a portion of the total cortex was isolated. The fragments obtained 
from several embryos were subjected to mechanic digestion for 5 min. Cells were then 
re-suspended in Neurobasal medium with 2% B-27 and seeded in 96-well black plates, 
at a density of 30.000 cells/well. Neuronal cultures were allowed to mature for 8 – 10 
days and, when the microscope showed the existence of a dense neuronal network, 
experiments were performed. Cells were loaded with 3 μM of Fluo-4/AM for 45 min at 
37 °C in Krebs-HEPES with the composition (in mM): 144 NaCl, 5.9 KCl, 2.5 MgCl2, 
10 glucose, 10 HEPES, 2 Ca2+; pH 7.4 at room temperature. During this time, Fluo-4 
dye, in its acetoxymethyl ester form, easily crosses the cell membrane by passive 
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diffusion, where is hydrolyzed by intracellular esterases to the Ca2+-sensitive, fully 
active Fluo-4 fluorescent dye in its carboxylate form, which is thus unable to leak back 
to the extracellular media. Then, cells were washed with Krebs-HEPES solution twice, 
removing the spare Fluo-4/AM still present in the extracellular medium. Compounds 
dissolved in Krebs-HEPES at the concentration desired were incubated for 10 min. In 
the case of assessing their IC50, compounds were assayed at least at four different 
concentrations, ranging from 1 to 100 μM. A batch of cells were incubated only with 
vehicle and considered as the positive control of the maximal [Ca2+]i expected upon the 
administration of NMDA. Application of NMDA 10 μM induced the opening of the 
NMDA-sensitive glutamate receptors and the subsequent [Ca2+] increase. The 
experiments were carried out at room temperature. Fluorescence was measured in a 
fluorescence microplate reader (FLUOstar Optima, BMG, Germany). Wavelengths of 
excitation and emission were 485 and 520 nm, respectively. At the end of the 
experiment, Triton X-100 (5%) was applied and the maximal fluorescence, i.e. Fmax, in 
each well was obtained. Then, MnCl2 1M was applied and the basal fluorescence, i.e. 
Fmin, in each well was obtained. Data were represented as percentage of fluorescence 
increase with respect to control, according to the formula ΔF/ ΔFcontrol ×100, where ΔF 
and ΔFcontrol are the percent increases of fluorescence with respect to the Fmax−Fmin 
interval in each well. 
In Vitro Blood–Brain Barrier Permeation Assay (PAMPA-BBB): Prediction of the brain 
penetration was evaluated using a parallel artificial membrane permeation assay for the 
blood-brain barrier (PAMPA-BBB), in a similar manner as previously described [21-
24]. Pipetting was performed with a semi-automatic pipettor (CyBi®-SELMA) and UV 
reading with a microplate spectrophotometer (Multiskan Spectrum, Thermo Electron 
Co.). Commercial drugs, phosphate buffered saline solution at pH 7.4 (PBS), and 
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dodecane were purchased from Sigma, Aldrich, Acros, and Fluka. Millex filter units 
(PVDF membrane, diameter 25 mm, pore size 0.45 μm) were acquired from Millipore. 
The porcine brain lipid (PBL) was obtained from Avanti Polar Lipids. The donor 
microplate was a 96-well filter plate (PVDF membrane, pore size 0.45 μm) and the 
acceptor microplate was an indented 96-well plate, both from Millipore. The acceptor 
96-well microplate was filled with 200 μL of PBS:ethanol (70:30) and the filter surface 
of the donor microplate was impregnated with 4 μL of porcine brain lipid (PBL) in 
dodecane (20 mg mL-1). Compounds were dissolved in PBS: ethanol (70:30) at 100 μg 
mL-1, filtered through a Millex filter, and then added to the donor wells (200 μL). The 
donor filter plate was carefully put on the acceptor plate to form a sandwich, which was 
left undisturbed for 120 min at 25 ºC. After incubation, the donor plate is carefully 
removed and the concentration of compounds in the acceptor wells was determined by 
UV-Vis spectroscopy. Every sample is analyzed at five wavelengths, in four wells and 
at least in three independent runs, and the results are given as the mean ± standard 
deviation. In each experiment, 10 quality control standards of known CNS permeability 
were included to validate the analysis set. 
In Vitro toxicity: The cytotoxicity was assessed using resazurin non-fluorescent dye 
(Alamar Blue assay) that is reduced by dehydrogenases of viable cells into resorufin a 
fluorescent dye [26]. The day before experiments cells obtained from the American 
Type Culture Collection HepG2, a human derived liver hepatocellular carcinoma cell 
line (ATCC® HB-8065™), were seeded at 2 x 104 cells per well in 96 well tissue 
culture plates, in 100 l of RPMI 1640 culture medium supplemented with 10% fetal 
bovine serum, 100 units of penicillin G (sodium salt), 100 mg of streptomycin sulfate 
and 2mM L-glutamine, at a concentration that allows cells to grow exponentially during 
the assay. 
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Tested compounds were dissolved in dimethyl sulfoxide (DMSO) serially diluted in the 
culture medium and added to the cells. The final concentration of DMSO in culture 
medium during treatment did not exceed 0.5% (v/v), and the same concentration of 
DMSO was added to the control. Each compound concentration was tested in triplicate 
in three independent experiments. Cells were incubated at 37 ºC in humidified 5% CO2 
atmosphere. After 28 h, resazurin dye solution was added to each well to a final 
concentration of 2.5 g/mL, after 3 h of incubations the fluorescence was measured 
(excitation, 530 nm; emission, 590 nm) in a microplate reader (FLUOstar Omega, BMG 
Labtech, Germany).  
The relative cell viability (%) compared to control cells was calculated by 
[Fluorescence]sample*100%./[Fluorescence]control. 
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Supplementary data associated with this article can be found in the online version. 
These data include: 1H and 13C NMR spectra for compounds 1c, 1d and 5b. 
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Twenty two novel enantiopure bicyclic lactams were synthesized and evaluated as 
NMDA receptor antagonists. The most promising compound displayed an IC50 value in 
the same order of magnitude of memantine. In vitro assays indicate that this compound 
is brain permeable (determined by an in vitro assay) and non-hepatotoxic, being a 
potential candidate for the treatment of pathologies associated with the overactivation of 
NMDA receptors. 
 
 
 
